Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • June 29, 2022

The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion

InMed Pharmaceuticals’ Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office’s Force For Knowledge Cannabis Symposium: The Intersection Between Medical and Health & Wellness to talk about the importance of evidence-based research of cannabinoids. They discuss the need to provide medical professionals and consumers data and research-supported information to enable informed decision making.

They discuss the increasing interest in the physiological effects of rare cannabinoids and how recent research is unveiling the potential benefits. Radicle Science is conducting a large scale study, “Radicle Energy rare cannabinoid study”, on the effects of THCV on energy, focus/attention, appetite and weight/BMI.

Panel 3: The Intersection Between Medical and Health & Wellness
A discussion of the opportunities in pharmaceutical industry in addition to current health & wellness uses.

  • Shane Johnson, SVP, BayMedica a Division of InMed Pharmaceuticals
  • Jeff Chen, MD & MBA, CEO & Co-founder, Radicle Science
  • Mitch Baruchowitz, Founder & Managing Partner, Merida Capital Holdings

Event website: https://forcefamilyoffice.com/events/technology/force-for-knowledge-cannabis-symposium-panel-3-view-on-demand/

Panel discussion here: https://vimeo.com/725509153

 

Full Article
Source: Force Family Office

Share this post

Latest Articles

How Could a Change in Legislation Affect the Cannabinoid Industry?

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how a change in legislation could impact the bioidentical cannabinoid manufacturing industry. In this interview,

Read More
May 16, 2023

BayMedica’s Bioidentical Rare Cannabinoids Fill a Market Need for Large Scale Batch-to-batch Consistency

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year. Jerry contributes

Read More
May 8, 2023

The Dales Report: InMed’s Latest Milestones Explained

InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed’s latest milestones including the latest on the Phase 2

Read More
April 19, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent